← Back to Clinical Trials
Recruiting NCT06914219

NCT06914219 Implementing an Interdisciplinary Eating Disorder Screening and Treatment Program for Post-Bariatric Surgery Patients in Nova Scotia

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06914219
Status Recruiting
Phase
Sponsor Aaron Keshen
Condition Bariatric Surgery Patients
Study Type INTERVENTIONAL
Enrollment 250 participants
Start Date 2026-03-04
Primary Completion 2027-05

Eligibility & Interventions

Sex All sexes
Min Age 19 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Treatment and Evaluation for After Metabolic Surgery with Eating Disorders (TEAM-ED) Program

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 250 participants in total. It began in 2026-03-04 with a primary completion date of 2027-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this interventional study is to evaluate the Treatment and Evaluation for After Metabolic Surgery with Eating Disorders (TEAM-ED) program, which combines streamlined access to screening, diagnostic assessment, and treatment with an interdisciplinary team approach to treatment planning, for managing disordered eating in adults who have recently had weight loss surgery in Nova Scotia. The main question it aims to answer is 'can an interdisciplinary program for identifying and managing disordered eating after weight loss surgery be implemented in Nova Scotia? This study will determine the feasibility and impact of the TEAM-ED program by assessing the following objectives: 1. Reach (how effectively the program engages the target population \[post-weight loss surgery patients\]) 2. Effectiveness (the extent of the program's impact on key clinical outcomes related to disordered eating and weight management) 3. Adoption (the extent to which the program is adopted and accepted by clinicians) 4. Implementation (how consistent program delivery is and factors impacting consistent delivery) Participants will complete a disordered eating screening questionnaire online every 3 months after weight loss surgery until they reach 18-months post-surgery. Participants found to have disordered eating will be referred to the Nova Scotia Provincial Eating Disorder Service (NSEDPS) for standard disordered eating treatment (brief cognitive behavioral therapy \[CBT-T\]) plus treatment plan oversight by both weight loss surgery and eating disorder specialists. Standard outcome measures will be collected at baseline, during eating disorder treatment, post-treatment, and at follow-ups. Participants may also be asked to do a one-on-one research interview about their experiences with the program.

Eligibility Criteria

Inclusion Criteria: * ≥19 years old * Between 3- and 18-months post-weight loss surgery. * Able to complete English computer-based self-report questionnaires (with adequate accommodation, if necessary).

Contact & Investigator

Central Contact

Aaron Keshen, MD

✉ aaron.keshen@nshealth.ca

📞 902-449-8228

Principal Investigator

Aaron Keshen, MD

PRINCIPAL INVESTIGATOR

Nova Scotia Health Authority

Frequently Asked Questions

Who can join the NCT06914219 clinical trial?

This trial is open to participants of all sexes, aged 19 Years or older, studying Bariatric Surgery Patients. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06914219 currently recruiting?

Yes, NCT06914219 is actively recruiting participants. Contact the research team at aaron.keshen@nshealth.ca for enrollment information.

Where is the NCT06914219 trial being conducted?

This trial is being conducted at Halifax, Canada.

Who is sponsoring the NCT06914219 clinical trial?

NCT06914219 is sponsored by Aaron Keshen. The principal investigator is Aaron Keshen, MD at Nova Scotia Health Authority. The trial plans to enroll 250 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology